Apeloa Pharmaceutical Co

Apeloa Pharmaceutical Co FCF/Debt

The Free Cash Flow to Debt Ratio of Apeloa Pharmaceutical Co (000739.SZ) as of Oct 22, 2026 is 55.78 %. In the previous year, Free Cash Flow to Debt Ratio was 83.31 % — a change of -33.05% (lower).

FCF/Debt

55.78 %

YoY

-33.05%

Last updated:

Free Cash Flow to Debt Ratio of Apeloa Pharmaceutical Co is 2025 55.78 % . Free Cash Flow to Debt Ratio of Apeloa Pharmaceutical Co was 2024 83.31 % . It decreases by -33.05% lower compared to the previous year.

The Apeloa Pharmaceutical Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
109.47 CNY
Jan 1, 2019
1,088.71 CNY
Jan 1, 2020
224.78 CNY
Jan 1, 2021
-19.59 CNY
Jan 1, 2022
98.64 CNY
Jan 1, 2023
48.24 CNY
Jan 1, 2024
83.31 CNY
Jan 1, 2025
55.78 CNY
The Apeloa Pharmaceutical Co FCF/Debt history
YEARFCF/DebtYoY
55.78 %-33.05%
83.31 %+72.69%
48.24 %-51.09%
98.64 %-603.58%
-19.59 %-108.71%
224.78 %-79.35%
1,088.71 %+894.53%
109.47 %+2,527.12%
4.17 %-133.10%
-12.59 %+1,230.86%
-0.95 %-103.40%
27.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apeloa Pharmaceutical Co Stock analysis

What does Apeloa Pharmaceutical Co do? Apeloa Pharmaceutical Co., Ltd. generates revenue through the research, development, and production of active pharmaceutical ingredient (API) intermediates, contract development and production services (CDMO), and preparations. The company’s main products include bulk drugs, intermediates, chemical preparations, and Chinese traditional medicine preparations such as ubenimex capsules, cefixime, and amantadine. These products are sold to both domestic and overseas markets, with the company distributing its offerings across these segments. The firm’s business model focuses on serving pharmaceutical manufacturers and healthcare providers through its comprehensive range of API intermediates and finished preparations. The company’s revenue streams are derived from the sale of bulk drugs, intermediates, and chemical preparations, alongside its Chinese traditional medicine preparations like ubenimex capsules and cefixime. These products are targeted at pharmaceutical manufacturers seeking API intermediates and finished drug formulations. Apeloa Pharmaceutical serves both domestic and international clients, with its products distributed in both markets. The company’s CDMO services further support clients in the development and production of pharmaceutical products. Apeloa Pharmaceutical’s core business involves the production and sale of API intermediates, bulk drugs, and various preparations, including traditional Chinese medicine products. The company’s main customers are pharmaceutical manufacturers and healthcare providers who require intermediates for drug manufacturing and finished preparations for market distribution. Its domestic and overseas market presence ensures a diversified revenue base, with products like ubenimex capsules and amantadine contributing to its product portfolio. Apeloa Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apeloa Pharmaceutical Co stock

Free Cash Flow to Debt Ratio of Apeloa Pharmaceutical Co is 55.78 % in 2025.

Free Cash Flow to Debt Ratio of Apeloa Pharmaceutical Co changed from 83.31 % to 55.78 %, representing a -33.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Apeloa Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Apeloa Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Apeloa Pharmaceutical Co

All Key Metrics — Apeloa Pharmaceutical Co